Posted on: Tue 03-11-2026

A more affordable version of a groundbreaking HIV prevention injection has received regulatory approval, raising hopes that millions more people around the world could gain access to one of the most effective tools for preventing HIV infection.

The long-acting shot, designed to provide protection against HIV without the need for a daily pill, has been hailed by health experts as a major advance in global HIV prevention efforts. The approval of a lower-cost version is expected to improve access in low- and middle-income countries where high prices have often limited availability.

Public health advocates say the development could significantly expand the reach of HIV prevention programmes, particularly among populations at higher risk of infection. By reducing costs, governments and international health organisations may be able to offer the injection to a larger number of people while stretching limited healthcare budgets further.

Experts believe the approval marks an important step toward narrowing the gap between medical breakthroughs and real-world access. While highly effective HIV prevention treatments have existed for years, affordability has remained a major obstacle in many parts of the world.

The newly approved version is expected to support global efforts to reduce new HIV infections and accelerate progress toward ending the AIDS epidemic as a public health threat. Health officials stress that prevention injections should be used alongside other strategies, including regular testing, education, and access to treatment services.

The announcement has been welcomed by global health organisations, which view wider access to innovative HIV prevention tools as a critical component of efforts to curb transmission and save lives in communities most affected by the virus.

---

---